Autoinjectors Market Report 2025 - Key Trends Include Personalized Drug Delivery, Smart and Needle-Free Devices, Biologic Delivery and Enhanced Safety Features - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)--The "Autoinjectors Market Report 2025" has been added to ResearchAndMarkets.com's offering.

This Autoinjectors market report covers market characteristics, size & growth, segmentation, regional & country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The autoinjectors market size has grown exponentially in recent years. It will grow from $3.7 billion in 2024 to $4.55 billion in 2025 at a compound annual growth rate (CAGR) of 22.8%. The growth in the historic period can be attributed to increased prevalence of chronic diseases, growth in aging population, rise in biotechnology and pharmaceutical sector, rise in patient preference for self-administration, regulatory support.

The autoinjectors market size is expected to see exponential growth in the next few years. It will grow to $10.07 billion in 2029 at a compound annual growth rate (CAGR) of 22%. The growth in the forecast period can be attributed to expansion of Therapeutic applications, rising healthcare costs, increased focus on patient-centered care, telemedicine and remote patient monitoring, emerging markets.

Major trends in the forecast period include personalized drug delivery, connected and smart autoinjectors, needle-free autoinjectors, biologic drug delivery, safety and security features.

The rising prevalence of chronic diseases is expected to drive growth in the autoinjectors market in the upcoming years. Chronic diseases are defined as illnesses that last for a year or longer and require ongoing medical attention. Conditions such as heart disease, cancer, rheumatoid arthritis, and diabetes are among the leading causes of mortality and disability worldwide. Autoinjector devices are designed for multiple injections of biologics and hormones in patients who need regular doses for the long-term management of conditions like diabetes and rheumatoid arthritis.

Rising healthcare expenditure is anticipated to boost the autoinjectors market. Healthcare expenditure refers to the total amount of money spent on healthcare services, goods, and activities within a specific healthcare system or economy over a defined period. Increased healthcare expenditure supports the development, affordability, and accessibility of autoinjectors for patients. Moreover, greater demand for autoinjectors can drive innovation in the field of autoinjector development.

The rise of technological advancements is significantly influencing the autoinjectors market. Key players in the autoinjectors sector are concentrating on developing innovative solutions to fulfill the demand for a delivery mechanism for viscous biologics. For example, in May 2023, Boehringer Ingelheim, a Germany-based pharmaceutical company, announced that its Cyltezo Pen, an autoinjector option for Cyltezo (adalimumab-adbm), received approval from the U.S. Food and Drug Administration (FDA). Cyltezo is authorized for the treatment of various chronic inflammatory diseases. The 40 mg/0.8 mL pre-filled Cyltezo Pen will be available in packs of two, four, and six.

Major companies in the auto-injectors market are focused on developing innovative products to address the growing demand for sustainable drug delivery devices while offering more cost-effective solutions for self-administered drug delivery. One such innovative product is the Qfinity auto-injector platform, designed to be both sustainable and affordable. The platform incorporates durable materials capable of withstanding over 100 injections and features a pre-filled disposable cassette system that minimizes waste.

Major companies operating in the autoinjectors market include AbbVie Inc., Mylan N.V., Eli Lilly and Company, Amgen Inc., Becton, Dickinson and Company, Johnson & Johnson, Teva Pharmaceutical Industries Ltd., Merck & Co. Inc., Pfizer Inc., Bayer AG, Biogen Inc., AstraZeneca PLC, Haselmeier GmbH, Owen Mumford Ltd., Gerresheimer AG, Philip Morris International Inc., Oval Medical Technologies Ltd., Solteam Incorporation Co. Ltd., Elcam Medical Group (E3D) Ltd., Jabil Inc., Catalent Inc., SHL Medical AG, West Pharmaceutical Services Inc., Nemera Development S.A., Bespak Europe Ltd., AptarGroup Inc., Consort Medical plc, Terumo Corporation, Nipro Corporation, Medtronic plc, Integra LifeSciences Corporation, OssDsign AB, Xenco Medical LLC, Renishaw plc.

This report focuses on autoinjectors market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

Markets Covered:

• By Type: Disposable Autoinjectors; Reusable Autoinjectors
• By Therapy: Rheumatoid Arthritis; Multiple Sclerosis; Diabetes; Anaphylaxis; Other Therapies
• By Route Of Administration: Subcutaneous; Intramuscular
• By Distribution Channel: Online Retailer; Pharmacy
• By End User: Home Care Settings; Hospitals And Clinics; Other End-Users

Subsegments:

• By Disposable Autoinjectors: Single-Use Disposable Autoinjectors; Pre-filled Disposable Autoinjectors
• By Reusable Autoinjectors: Multi-Use Reusable Autoinjectors; Rechargeable Reusable Autoinjectors

   

Key Attributes:

Report Attribute	Details
No. of Pages	200
Forecast Period	2025 - 2029
Estimated Market Value (USD) in 2025	$4.55 Billion
Forecasted Market Value (USD) by 2029	$10.07 Billion
Compound Annual Growth Rate	22.0%
Regions Covered	Global

Company Coverage:

• AbbVie Inc.
• Mylan N.V.
• Eli Lilly and Company
• Amgen Inc.
• Becton, Dickinson and Company
• Johnson & Johnson
• Teva Pharmaceutical Industries Ltd.
• Merck & Co. Inc.
• Pfizer Inc.
• Bayer AG
• Biogen Inc.
• AstraZeneca PLC
• Haselmeier GmbH
• Owen Mumford Ltd.
• Gerresheimer AG
• Philip Morris International Inc.
• Oval Medical Technologies Ltd.
• Solteam Incorporation Co. Ltd.
• Elcam Medical Group (E3D) Ltd.
• Jabil Inc.
• Catalent Inc.
• SHL Medical AG
• West Pharmaceutical Services Inc.
• Nemera Development S.A.
• Bespak Europe Ltd.
• AptarGroup Inc.
• Consort Medical
• Terumo Corporation
• Nipro Corporation
• Medtronic plc
• Integra LifeSciences Corporation
• OssDsign AB
• Xenco Medical
• Renishaw

For more information about this report visit https://www.researchandmarkets.com/r/3jhucf

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.